Journal
NATURE STRUCTURAL & MOLECULAR BIOLOGY
Volume 28, Issue 6, Pages 460-462Publisher
NATURE PORTFOLIO
DOI: 10.1038/s41594-021-00606-5
Keywords
-
Funding
- National Cancer Institute (NCI) of the NIH [R35CA232115, R01CA233671]
Ask authors/readers for more resources
The RNA methyltransferase METTL3 plays a crucial role in cancer development and progression, particularly in AML. A selective small molecule inhibitor of METTL3 has shown promising antileukemic effects in preclinical models, suggesting a potential new cancer therapy targeting METTL3.
The RNA methyltransferase METTL3 catalyzes N-6-methyladenosine (m(6)A) modification of messenger RNAs (mRNAs). It is overexpressed in many types of cancer, including acute myelogenous leukemia (AML), and promotes cancer cell growth and tumorigenicity. Now, a selective small molecule inhibitor of METTL3 shows significant antileukemic effects in preclinical AML models, highlighting the promise of pharmacological METTL3 inhibition as a new cancer therapy.
Authors
I am an author on this paper
Click your name to claim this paper and add it to your profile.
Reviews
Recommended
No Data Available